Devin Hosea has been operating and investing in technology ventures for almost 20 years. Professionally, he has worked in buy-side investing, starting as a research analyst for Alliance Bernstein, then as Vice President for Technology Ventures at GE Capital, as Managing Director of Biotechnology Ventures for Ritchie Capital Management, and then as Managing General Partner for Interventure Capital. During his investment career, he “dropped in” to restructure and run three companies: Vanguard Automation (from bankruptcy to $67m sale), Subscriber Computing ($80m sale of a company GE had written off entirely), and American Biophysics Corporation (a company focused on combating malaria with technology).
Academically, Mr. Hosea has focused on artificial intelligence. After graduating from Princeton University, he was awarded a National Science Foundation fellowship, where his research focused on hybrid reasoning, decision support systems, and the practical implementation of automated reasoning in medical applications. He patented the results of his work as an NSF Fellow, and also published them. He is currently the primary or co-inventor on over a dozen issued patents, with several pending. He has taught at Harvard Business School and has also been an invited speaker at several prestigious conferences, including the Fortune Global Economic Forum. In 2001, Fortune Magazine named Devin one of the top 100 most influential technologists in the United States.
Entrepreneurially, Mr. Hosea founded and ran Predictive Networks in 1998 and served as its Chief Executive Officer until 2002. He not only conceived of the core technology and business model for Predictive Networks, but also raised about $50 million in venture financing from Battery Ventures, Intel Capital, Advent International, Nielsen, NTT (Japan), and others. He has also helped launch Aviir (a cardiology diagnostics company out of Stanford Medical School), co-founded Telesecret (a VOIP cryptography company), and started Acoustic Surgery Corporation (an ultrasound sonothrombolysis company). He has served on the Board of Directors of over a dozen venture-backed companies in his career, and currently is Chairman of Syringex Medical, Inc. and is the lead independent director of its Hong Kong subsidiary.
Daniel Saal is a clinician, scientist, inventor, and academic who has dedicated his career to treating addiction. He most recently served as Medical Director of Kaiser Permanente’s Chemical Dependence Program, where he managed a staff of MDs, NPs, psychologists, and other clinicians. Dr. Saal and his team handled treatment of addiction issues for a catchment of 420,000 patients in the San Francisco Bay Area.
Prior to entering clinical work, he spent six years as an academic, starting as a post- doc at Stanford University Department of Psychiatry, and going on to serve as a professor of medicine at Emory University. During this time, and throughout his career, Dr. Saal has published many articles in prestigious publications - one in particular found a common correlation amongst the neurophysiological pathways of all drugs of misuse - and is now widely cited in the literature. His research has also suggested novel pharmacologic treatment of stress and addiction. Dr. Saal has not only studied the neuroscience of addiction, but he has applied his findings to the clinical environment. For his research and throughout his career, Dr. Saal has received numerous grants and awards from both government agencies (e.g. the National Institutes of Health) and private industry (e.g. Pfizer Corporation). Dr. Saal received his MD and PhD from Yale University and his BS from the Massachusetts Institute of Technology.
Richard Lawrence is a lawyer who has advised on a wide variety of financing, joint venture, M&A, energy and infrastructure and technology transactions in Asia, Latin America and the United States. Among other areas of expertise, he is an expert at negotiating and documenting very complex contracts with government entities and heavily regulated companies. Prior to joining PredictiCare he was resident partner and chief representative of Holland & Knight in Beijing. Mr. Lawrence received his JD from Columbia Law School and his BA (Summa Cum Laude) from the University of Massachusetts, Amherst.
Matthew Clark has over three decades of software development and management experience. He has worked for RCA, General Electric, SRI International, and several smaller startup companies. At EZsize he led the development of a patented process for garment fit prediction, and at Data Description created a multimedia statistics education tool used by hundreds of thousands of higher-ed students. Prior to PredictiCare, Mr Clark was co-founder and CTO of a custom software company whose clients included Cornell University, PayPal, eBay, iControl Networks, and Pebble. He has special expertise in web application and wearables development, and technical skills include software architecture, back-end programming, database management, and system administration. Mr. Clark received his BS (Summa cum Laude) from Princeton University and his MSE from the University of Pennsylvania.
John Sammis has been involved with technology businesses for over 30 years, starting as a chemical engineer with IBM’s microelectronic business. In addition to engineering he has experience with marketing and sales, business development, operations, and project management. He was the President of a statistics software company where he led the development of an award-winning statistics software program, and managed several cutting-edge multimedia training projects funded by the National Science Foundation and the Centers for Disease Control and Prevention. Prior to PredictiCare, Mr. Sammis was the CEO of a custom software development company, where he managed the development of projects for clients such as Cornell University, Richemont, Inc, and Neighborworks America. He has special expertise in predictive modeling and has published a number of white papers and articles related to predictive modeling and fundraising analytics. Mr. Sammis received his BS in Chemical Engineering from Clarkson University and his MBA from Cornell University.
For more than three decades Brian Wiley has brought finance, operations, and business development expertise to companies in technology, telecommunications, healthcare, and investment banking . He has extensive experience in analysis, financial operations, and transactions focusing on smaller entities or divisions of larger organizations. He combines this experience with a background in corporate financial and valuation analysis, operational financial planning and analysis, operational management, equity and debt fundraising, M&A and IPOs, consulting and corporate development. Mr. Wiley received a AB from Princeton University and an MBA from New York University's Stern School of Business